Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder urothelial cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | cell lines (BUC, J82 and T24) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA PVT1 is overexpressed in multidrug resistant BUC tissues and cell lines, and PVT1 knockdown reduces BUC cell proliferation, invasiveness, and chemoresistance by modulating Wnt/B-catenin signaling. PVT1 was upregulated in BC, where it promoted tumor cell proliferation and suppressed apoptosis. |
| Pubmed ID | 28969069 |
| Year | 2017 |
| Title | LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for bladder urothelial cancer | OMIM COSMIC |